Managing Type 2 Diabetes Mellitus Through Innovative Therapeutic Treatment
Ramadan is not merely a time for spiritual reflection but also an opportunity to give the body time to “reset” through healthier eating patterns. The fasting period can provide metabolic benefits for some people, and healthy eating habits can contribute to the prevention of Diabetes Mellitus, which remains a significant health challenge for Indonesian society.
According to the International Diabetes Federation (IDF) Diabetes Atlas (2025), approximately 11.1%, or 1 in 9 adults (aged 20-79 years), live with diabetes, with more than 4 in 10 people unaware that they have the condition. More than 90% of Diabetes Mellitus cases are Type 2 Diabetes Mellitus, a chronic disease characterised by elevated blood glucose levels resulting from insulin resistance or insufficient insulin production.
This condition is influenced by various factors, including socio-economic, demographic, environmental, and genetic factors. Type 2 Diabetes Mellitus affects how the body uses glucose as an energy source and is the most common form of diabetes in adults.
The IDF Diabetes Atlas (2025) indicates that approximately 19.5 million adults live with Type 2 Diabetes Mellitus. This underscores the need for efforts to increase awareness, prevention, and access to new treatments for Type 2 Diabetes Mellitus.
Such efforts require cooperation and collaboration from various parties, including government, industry, and the public. Furthermore, management of Type 2 Diabetes Mellitus also requires comprehensive behavioural change, ranging from implementing healthy eating habits, regular physical activity, stress management, to maintaining sleep quality.
In addition to these efforts, individually tailored treatment plans under healthcare professional supervision can also help people with Type 2 Diabetes Mellitus manage their condition more effectively.
“As a leading healthcare services company, APL is committed to delivering groundbreaking innovative products and improving access to healthcare services for communities across Indonesia. APL strives to bridge global breakthroughs with the real needs of patients in Indonesia, making healthcare services more accessible,” said President Director of PT Anugerah Pharmindo Lestari (APL), Christophe Piganiol.
To address the needs of patients in Indonesia, APL is providing practical solutions through its expertise in distribution, commercialisation, and clinical trial services. APL is bringing new treatment options to Indonesia, for example Tirzepatide, a medication with a new mechanism of action for Type 2 Diabetes Mellitus. Tirzepatide is a dual receptor antagonist that combines GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). APL will also ensure that this therapy is accessible to patients throughout Indonesia.
The objective of improving healthcare services through the introduction of new therapeutic treatments cannot be realised without the important role of the Indonesian Drug and Food Regulatory Authority (BPOM). BPOM’s vision for 2025-2029 focuses on regulating safe, high-quality, and competitive medicines and food products to realise a healthy and prosperous society and support the achievement of Indonesia Emas 2045. BPOM plays a crucial role in ensuring that Tirzepatide can quickly reach patients through an accelerated registration pathway.
With an evaluation period of only 98 days, BPOM approved distribution authorisation for this new molecule whilst maintaining the highest safety and integrity standards. APL appreciates BPOM’s performance, which is a crucial factor in providing confidence in the choice of new therapeutic treatments needed by healthcare professionals and patients in Indonesia.
Access to high-quality Type 2 Diabetes Mellitus treatment is a step forward in addressing this disease whilst bringing hope to more patients in Indonesia to receive the latest therapy.